RAD BioMed

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

CVAid Medical is focused on advancing stroke care through its innovative artificial intelligence-based stroke detection platform. This technology is designed to enhance stroke diagnosis and improve patient outcomes by facilitating early triage. The company provides a comprehensive solution that spans the entire stroke care continuum, including pre-hospital early diagnosis, in-hospital process management, and follow-up care after patient discharge. By enabling healthcare professionals to make timely and informed decisions, CVAid Medical aims to significantly enhance treatment effectiveness and potentially save lives.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

SoftWheel is a technology company based in Tel Aviv, Israel, that specializes in developing advanced in-wheel suspension systems. Founded in 2011, the company focuses on enhancing personal mobility by creating innovative suspension solutions for wheelchairs, bicycles, and automobiles. SoftWheel's products include suspension arms and wheel rims, which are designed to absorb shocks and vibrations while providing rigidity and stability. The company operates through a network of resellers both domestically in Israel and internationally. It has established strategic partnerships with leading global companies such as NSK and Linamar to drive sustainable transportation and improve people’s lives through innovative technology.

Advanced Ophthalmic Pharma Ltd., a biomedical company, develops technologies in ophthalmology. It offers Eye AdMister, a drug delivery device, enables the mist application of preservative-free ophthalmic drug formulations for eye care. The company was founded in 2007 and is based in Tel Aviv, Israel.

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.